FDA warns SaNOtize that NOWONDER Nasal Cleanser is an unapproved new drug sold in the U.S. with antiviral claims.
What happened
On February 17, 2026, FDA reviewed SaNOtize’s product labeling, including the websites nowonder.com and sanotize.com, where NOWONDER Nasal Cleanser was available for purchase in the U.S. without a prescription. FDA found claims that the nasal cleanser fights germs, viruses, bacteria, influenza, and SARS-CoV-2, and that it supports immune defense. FDA concluded the product is a drug and an unapproved new drug because no FDA-approved application is in effect for it.
What FDA found
FDA says the product is a drug because the labeling claims it can prevent or treat disease, such as colds, flu, or infections.
FD&C Act section 201(g)(1)(B), 21 U.S.C. 321(g)(1)(B)FDA says the product is also a drug because the labeling claims it affects the structure or function of the body, such as boosting natural defenses.
FD&C Act section 201(g)(1)(C), 21 U.S.C. 321(g)(1)(C)FDA says the product is an unapproved new drug because it is not generally recognized as safe and effective for its labeled uses and no FDA-approved application is in effect for it.
FD&C Act section 505(a), 21 U.S.C. 355(a)FDA says selling the product across state lines without an approved application is prohibited.
FD&C Act section 301(d), 21 U.S.C. 331(d)
What FDA wants
FDA tells SaNOtize to notify FDA in writing within 15 working days of receipt of the letter about specific corrective steps, with explanations and documentation, or to explain any delay and when correction will be complete.
Who should pay attention
- retailers and online marketplaces offering NOWONDER in the U.S.
- other nasal spray or consumer health brands making antiviral or immune-defense claims
- companies selling Canadian consumer health products into the U.S.
This is a summary. Read the original letter on fda.gov.